Trends in targeted therapy usage in inflammatory bowel disease: TRENDY study of ENEIDA

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Gómez-Labrador, Celia
• dc.contributor.author Márquez-Mosquera, Lucía
• dc.contributor.author Gisbert, Javier P.
• dc.date.accessioned 2025-07-11T07:02:41Z
• dc.date.available 2025-07-11T07:02:41Z
• dc.date.issued 2024
• dc.description.abstract Markers that allow for the selection of tailored treatments for individual patients with inflammatory bowel diseases (IBD) are yet to be identified. Our aim was to describe trends in real-life treatment usage. For this purpose, patients from the ENEIDA registry who received their first targeted IBD treatment (biologics or tofacitinib) between 2015 and 2021 were included. A subsequent analysis with Machine Learning models was performed. The study included 10,009 patients [71% with Crohn's disease (CD) and 29% with ulcerative colitis (UC)]. In CD, anti-TNF (predominantly adalimumab) were the main agents in the 1st line of treatment (LoT), although their use declined over time. In UC, anti-TNF (mainly infliximab) use was predominant in 1st LoT, remaining stable over time. Ustekinumab and vedolizumab were the most prescribed drugs in 2nd and 3rd LoT in CD and UC, respectively. Overall, the use of biosimilars increased over time. Machine Learning failed to identify a model capable of predicting treatment patterns. In conclusion, drug positioning is different in CD and UC. Anti-TNF were the most used drugs in IBD 1st LoT, being adalimumab predominant in CD and infliximab in UC. Ustekinumab and vedolizumab have gained importance in CD and UC, respectively. The approval of biosimilars had a significant impact on treatment.
• dc.format.mimetype application/pdf
• dc.identifier.citation Gómez-Labrador C, Ricart E, Iborra M, Iglesias E, Martín-Arranz MD, de Castro L, et al. Trends in targeted therapy usage in inflammatory bowel disease: TRENDY study of ENEIDA. Pharmaceutics. 2024 May 8;16(5):629. DOI: 10.3390/pharmaceutics16050629
• dc.identifier.doi http://dx.doi.org/10.3390/pharmaceutics16050629
• dc.identifier.issn 1999-4923
• dc.identifier.uri http://hdl.handle.net/10230/70893
• dc.language.iso eng
• dc.publisher MDPI
• dc.relation.ispartof Pharmaceutics. 2024 May 8;16(5):629
• dc.rights © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Crohn’s disease
• dc.subject.keyword Biologics
• dc.subject.keyword Biosimilars
• dc.subject.keyword Inflammatory bowel disease
• dc.subject.keyword Positioning
• dc.subject.keyword Targeted therapy
• dc.subject.keyword Trends
• dc.subject.keyword Ulcerative colitis
• dc.title Trends in targeted therapy usage in inflammatory bowel disease: TRENDY study of ENEIDA
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion